Latest Commercialisation News

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

St George Mining has expanded its Araxá rare earths-niobium resource by 75% to 70.91Mt at 4.06% TREO, positioning the project among the world’s largest carbonatite deposits. The company also acquired land for processing facilities and forged new downstream partnerships, supported by Minas Gerais state tax incentives.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Resolution Minerals has successfully produced high-grade tungsten concentrates from historical stockpiles at its Golden Gate mine, achieving a 19-fold upgrade and strong recovery rates using simple gravity separation techniques.

European Resources has more than doubled its Korsnäs rare earth resource following a successful drilling program and metallurgical advances, underpinning a $3.4 million capital raise to fund further development.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

First Graphene has secured advanced graphene coatings technology through the AU$250,000 acquisition of Ionic Industries and Imagine Intelligent Materials, gaining immediate entry into lucrative geotextile and environmental infrastructure sectors.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Lion Rock Minerals reported strong high-grade rutile and heavy mineral results at its Minta Project in Cameroon, expanding infill drilling and commissioning an in-country lab ahead of a maiden resource estimate targeted for H2 2026.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

QMines Limited’s latest drilling at Mount Mackenzie confirms a broad, structurally controlled high-grade gold system with multiple mineralised zones open at depth and along strike.